top of page

Media

Award Logo-Avotres.jpg

Press releases and recent developments at Avotres

​

  • January 5, 2024: Avotres has been nominated as one of the Top 10 Biotech Startups in 2023, by Pharma Tech Outlook.

  • June 25, 2023: Avotres presents the Day 150 results (primary readout) from its ongoing phase I/II study at 83rd Scientific Session of American Diabetes Association (ADA)

  • December 9, 2022: Avotres Announces Achieving Primary Endpoint of its Phase 1/2 Clinical Trial of AVT001 in Patients with Type 1 Diabetes

  • December 7, 2021: Avotres Announces Completion of Enrollment of its Phase I/II Trial of AVT001 in Patients with Type 1 Diabetes (T1D)

  • August 2, 2021: Avotres has appointed Dr. Bruce Cooper as independent board of director

  • August 2, 2021: Avotres announces appointment of John Houghton as President and Chief Executive Officer

  • June 22, 2021: Avotres received FDA written response to the MS pre-IND briefing book

  • May 21, 2021: Avotres submitted a pre-IND briefing book to FDA for a multiple sclerosis (MS) study with its cell therapy, AVT001

  • April 16, 2021: Avotres signed an agreement with American Red Cross (ARC) to collaborate on the leukapheresis of adolescent patients for for its ongoing phase 1/2 Type 1 Diabetes (T1D) study

  • March 19, 2021: received the approval letter from the Institutional Review Board (IRB) of Joslin Diabetes Center, Harvard Medical School, to expand its ongoing phase 1/2 Type 1 Diabetes (T1D) study to adolescent T1D patients aged 16 and 17

  • February  19, 2021: wrapped up a clinical advisory board with focus on discussing clinical trial design for a multiple sclerosis study with its cell therapy, AVT001

  • February 3, 2021: signed a contract with T1D Exchange, a patient advocacy group, to collaborate on patient recruitment for its ongoing phase 1/2 Type 1 Diabetes (T1D) study

  • September 9, 2020: Avotres received the approval letter from the Institutional Review Board (IRB) from the department of dermatology, University of Pennsylvania, to initiate human ex vivo studies of AVT001 in patients with cutaneous lupus, pemphigus and dermatomyositis

  • June 19, 2020: Avotres received the approval letter from the Institutional Review Board (IRB) from the department of neurology, Icahn School of Medicine at Mount Sinai, to initiate human ex vivo studies of AVT001 in patients with relapse remitting and progressive multiple sclerosis

  • April 17, 2020: Avotres was chosen as one of the top 40 startup companies across four industry sectors including pharmaceuticals, in the Spinoff  Prize contest, a worldwide competition hosted by Nature Research, the publisher of Nature, and has been featured in a special report published in Nature https://www.nature.com/articles/d41586-020-01904-6

  • April 2, 2020: 2nd Drug Safety Monitoring Board (DSMB) meeting completed the review of the safety data of first 6 dosed patients with recommendation to continue the AVT001-T1D-01 clinical trial

  • March 2, 2020: received the approval letter from the Institutional Review Board (IRB) from the department of dermatology, Icahn School of Medicine at Mount Sinai, to initiate human ex vivo studies of AVT001 in patients with psoriasis, psoriatic arthritis, pemphigus and vitiligo

  • December 21, 2019: Internationally renowned authority on the scientific and clinical aspects of multiple sclerosis, Dr. Fred Lublin, the Saunders Family Professor of Neurology and the Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai Medical Center, signed on as a member of Avotres Scientific Advisory Board

  • December 3, 2019: 1st Drug Safety Monitoring Board (DSMB) meeting completed the review of the safety data of first 3 dosed patients with recommendation to continue AVT001-T1D-01 clinical trial

  • September 27, 2019: Dr. Jay Skyler, a world top ranking experts in type 1 diabetes with 5 decades of experience in diabetes clinical research, Professor of Medicine, Pediatrics, & Psychology at University of Miami, signed on as a member of Avotres Scientific Advisory Board

  • September 12, 2019: conducted an advisory board meeting for AVT001 with focus on dermatology and rheumatology

  • August 26, 2019: completed 1st patient 1st dose for AVT001-T1D-01 clinical trial

  • July 17, 2019: A world-renowned immunologist, Dr. Harvey Cantor, Baruj Benacerraf Professor and Principal Investigator of Cancer Immunology and Virology at Dana-Farber Cancer Institute, and Professor of Immunology at Harvard Medical School, joined Avotres Scientific Advisory Board

  • June 20, 2019: completed 1st patient 1st visit for AVT001-T1D-01 clinical trial

  • June 12, 2019: completed Site Initiation Visit (SIV) at Joslin Diabetes Center, Harvard Medical School, for the combined phase I/II Type 1 Diabetes (T1D) clinical trial, AVT001-T1D-01 (NCT03895996, the official registry number of clinicaltrials.gov)

  • June 6, 2019: Dr. David Lebwohl, former Novartis senior VP and franchise global program head of the CAR-T program, joined Avotres Scientific Advisory Board

  • June 6, 2019: executed the Master Service Agreement (MSA) with IQVIA Biotech, a subsidiary of IQVIA, as the CRO for the combined combined phase I/II Type 1 Diabetes (T1D) clinical trial, AVT001-T1D-01 trial (NCT03895996, the official registry number of clinicaltrials.gov)

  • April 16, 2019: received the approval letter from the Institutional Review Board (IRB) of Joslin Diabetes Center, an affiliate of Harvard Medical School, for the clinical protocol of the combined phase I/II Type 1 Diabetes (T1D) clinical trial, AVT001-T1D-01 (NCT03895996, the official registry number of clinicaltrials.gov)

  • February 25, 2019: signed the Clinical Trial Agreement (CTA) with Joslin Diabetes Center, an affiliate of Harvard Medical School, for the combined phase I/II Type 1 Diabetes (T1D) clinical trial, AVT001-T1D-01 (NCT03895996, the official registry number of clinicaltrials.gov)

  • February 20, 2019: submitted to FDA the amendments of Investigational New Drug (IND) #15672 that include the clinical module and the transfer of sponsorship to Avotres

  • February 15, 2019: executed the contract with Dana-Farber Cancer Institute (DFCI), an affiliate of Harvard Medical School, to have its Cell Manufacturing Core Facility (DFCI/CMCF) as the Contract Manufacturing Organization (CMO) for AVT001, a cell therapy for autoimmune diseases and transplantation

  • January 30, 2019: acquired worldwide exclusive licence from Columbia University for the intellectual property rights of the Avotres platform

  • January 25, 2019: signed a limited service agreement  with IQVIA Biotech, a subsidiary of IQVIA, as the Clinical Research Organization (CRO) for Avotres

  • October 31, 2018: A world top ranking experts in psoriasis, Dr. Mark Lebwohl, Waldman Professor & Chairman of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai, signed on as a member of Avotres Scientific Advisory Board

bottom of page